Provided by Tiger Trade Technology Pte. Ltd.

Madrigal Pharmaceuticals

464.71
-9.0800-1.92%
Post-market: 455.69-9.0200-1.94%18:08 EST
Volume:245.70K
Turnover:114.88M
Market Cap:10.55B
PE:-35.65
High:482.99
Open:474.31
Low:458.07
Close:473.79
52wk High:615.00
52wk Low:265.00
Shares:22.71M
Float Shares:11.00M
Volume Ratio:0.71
T/O Rate:2.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0355
EPS(LYR):-21.9007
ROE:-41.22%
ROA:-15.78%
PB:16.87
PE(LYR):-21.22

Loading ...

Earning Preview: Madrigal Pharmaceuticals revenue is expected to increase by 217.06%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Doximity (DOCS) and Humana (HUM)

TIPRANKS
·
Feb 12

Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash

THOMSON REUTERS
·
Feb 11

BRIEF-Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs

Reuters
·
Feb 11

Madrigal, Suzhou Ribo in license deal for liver‑disease programs

Reuters
·
Feb 11

Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo

TIPRANKS
·
Feb 11

BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal

Reuters
·
Feb 11

Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science

Reuters
·
Feb 11

Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis

THOMSON REUTERS
·
Feb 11

Madrigal Pharmaceuticals Inc - Announces Exclusive Global License Agreement With Suzhou Ribo

THOMSON REUTERS
·
Feb 11

Madrigal Pharmaceuticals Inc - Ribo to Receive $60 Mln Upfront, Potential $4.4 Bln in Payments

THOMSON REUTERS
·
Feb 11

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Move

Simply Wall St.
·
Feb 08

Madrigal Pharmaceuticals Grants Equity Awards to New Employees

Reuters
·
Feb 06

BRIEF-Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule

Reuters
·
Feb 06

Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness

Simply Wall St.
·
Feb 05

Madrigal Pharmaceuticals Inc. to Release Fourth-Quarter and Full-Year 2025 Financial Results

Reuters
·
Feb 02

Madrigal Builds Commercial Bench With Equity Grants Around Rezdiffra Growth Story

Simply Wall St.
·
Feb 02

Madrigal Pharmaceuticals Inc - and Roche Enter Into First Amendment to Agreement - SEC Filing

THOMSON REUTERS
·
Jan 31

Madrigal Pharmaceuticals Inc - Co Gains Control Over Rezdiffra Patent Term Adjustments - SEC Filing

THOMSON REUTERS
·
Jan 31

Madrigal Pharmaceuticals Gains Patent Control for Rezdiffra in Amended Roche Agreement

Reuters
·
Jan 31